These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32156064)

  • 1. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.
    Beloglazkina A; Zyk N; Majouga A; Beloglazkina E
    Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
    Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
    Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.
    Qin JJ; Nag S; Voruganti S; Wang W; Zhang R
    Curr Med Chem; 2012; 19(33):5705-25. PubMed ID: 22830335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
    Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
    Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
    Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule MDM2-p53 inhibitors: recent advances.
    Zhang B; Golding BT; Hardcastle IR
    Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y; Aguilar A; Bernard D; Wang S
    J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.
    Wong JH; Alfatah M; Sin MF; Sim HM; Verma CS; Lane DP; Arumugam P
    BMC Biol; 2017 Nov; 15(1):108. PubMed ID: 29121928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of libraries targeting protein-protein interfaces.
    Fry D; Huang KS; Di Lello P; Mohr P; Müller K; So SS; Harada T; Stahl M; Vu B; Mauser H
    ChemMedChem; 2013 May; 8(5):726-32. PubMed ID: 23436619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
    Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
    Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
    Millard M; Pathania D; Grande F; Xu S; Neamati N
    Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.
    Estrada-Ortiz N; Neochoritis CG; Dömling A
    ChemMedChem; 2016 Apr; 11(8):757-72. PubMed ID: 26676832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
    Patel S; Player MR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
    Wang W; Hu Y
    Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
    He S; Dong G; Wu S; Fang K; Miao Z; Wang W; Sheng C
    J Med Chem; 2018 Aug; 61(16):7245-7260. PubMed ID: 30045621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
    Zanjirband M; Rahgozar S
    Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.